Bruce Cree — Biomedical Watch V2

Traitements5programmes

Essais1liés

Publications7liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Chemotherapy: cyclophosphamide (CYC)The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.	SEP	Phase 1	Ralentissement de la progression	United States	À vérifier
Chemotherapy: fludarabine (FLU)The goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.	SEP	Phase 1	Ralentissement de la progression	United States	À vérifier
KYV-101 (Biological) - 0.33 ×10^8 cellsThe goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.	SEP	Phase 1	Ralentissement de la progression	United States	À vérifier
KYV-101 (Biological) - 1 ×10^8 cellsThe goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.	SEP	Phase 1	Ralentissement de la progression	United States	À vérifier
KYV-101 (Biological) - 0.33 ×10^8 cellsThe goal of this study is to test a drug called KYV-101 in people who have progressive multiple sclerosis (MS) and who have not responded to standard therapies to slow disease progression. The main questions it aims to answer are: * What is the highest therapy dose that can be given without causing harm? * Can this therapy enter the central nervous system? Participants will be asked to: * Attend 14 visits plus an 8-day inpatient hospital stay over the course of 58 weeks. * Complete apheresis and chemotherapy treatments in preparation for KVY-101 therapy. * Undergo medical and research testing such as physical and neurological exams, MRI, lumbar puncture, blood draws, questionnaires, and vision assessments.	SEP	Phase 1	Thérapie cellulaire + Ralentissement de la progression + Immunomodulation	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
KYV-101 (Biological) - 0.33 ×10^8 cells	SEP	Phase 1	NCT06451159	A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis	ACTIVE_NOT_RECRUITING

Publications

7

Molécule	Indication / population	Titre	Journal	Date
Chemotherapy: fludarabine (FLU)		A Novel Modified Bu/Vp16/cy/Flu/Ara-C Conditioning Regimen Enhances Outcomes for High-Risk Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.	Cancer medicine
Chemotherapy: cyclophosphamide (CYC)		Evaluation of the effects of diosmin in cyclophosphamide-induced nephrotoxicity: an experimental animal study.	Naunyn-Schmiedeberg's archives of pharmacology
Chemotherapy: cyclophosphamide (CYC)		Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter.	Autoimmunity reviews
Chemotherapy: fludarabine (FLU)		Efficacy and Safety of Bendamustine Versus Fludarabine and Cyclophosphamide as Lymphodepleting Regimens for CAR-T Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis.	European journal of haematology
Chemotherapy: fludarabine (FLU)		Microbiota injury during conditioning for allogeneic hematopoietic stem cell transplantation.	Journal of medicine and life
Chemotherapy: cyclophosphamide (CYC)		Boric acid Attenuates premature ovarian insufficiency by Modulating oxidative stress in a Cyclophosphamide-Induced rat model.	European journal of obstetrics, gynecology, and reproductive biology
Chemotherapy: cyclophosphamide (CYC)		Hepatoprotective effect of dipyridamole against cyclophosphamide-induced hepatotoxicity in rats.	Open veterinary journal